Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/2436/15805
Title:
Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.
Authors:
Dutton, Amanda; Burns, Alan T. H.; Young, Lawrence S.; Murray, Paul G.
Abstract:
Hodgkin's lymphoma is one of the most common lymphoid cancers, particularly among young adults. Although there have been dramatic improvements in the treatment of Hodgkin's lymphoma, leading to high cure rates in some groups, current combination chemotherapy regimes are associated with significant secondary complications in long-term survivors. Furthermore, although a proportion of patients with Hodgkin's lymphoma will be cured, there still remains a significant rate of relapse and also a smaller proportion of poor responders who will go on to die of their disease. Therefore, developments in the treatment of Hodgkin's lymphoma must be directed at improving cure rates and reducing the burden of secondary complications. In recent years, the underlying pathogenesis of Hodgkin's lymphoma has become better understood. In particular, it is emerging that a key pathogenic event in Hodgkin's lymphoma is protection from Fas-induced cell death. Recent studies by the authors' group, and others, have demonstrated that this is, in part, due to the expression by Hodgkin/Reed-Sternberg cells of the cellular Fas-associated death domain-like IL-1 converting enzyme (FLICE)-like inhibitory protein molecule, a potent inhibitor of Fas-induced death. In this review, the role of cellular FLICE-like inhibitory protein in the pathogenesis of Hodgkin's lymphoma will be explored and also the possibility of targeting this molecule in order to provide an alternative and potentially safe approach to the treatment of Hodgkin's lymphoma will be investigated.
Citation:
Expert Review of Anticancer Therapy, 6(6): 911-919
Publisher:
Future Drugs
Issue Date:
2006
URI:
http://hdl.handle.net/2436/15805
DOI:
10.1586/14737140.6.6.911
PubMed ID:
16761935
Additional Links:
http://www.expert-reviews.com/doi/abs/10.1586/14737140.6.6.911
Type:
Article
Language:
en
Description:
Metadata only
ISSN:
1473-7140
Appears in Collections:
Cancer Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorDutton, Amanda-
dc.contributor.authorBurns, Alan T. H.-
dc.contributor.authorYoung, Lawrence S.-
dc.contributor.authorMurray, Paul G.-
dc.date.accessioned2008-01-08T10:59:02Z-
dc.date.available2008-01-08T10:59:02Z-
dc.date.issued2006-
dc.identifier.citationExpert Review of Anticancer Therapy, 6(6): 911-919en
dc.identifier.issn1473-7140-
dc.identifier.pmid16761935-
dc.identifier.doi10.1586/14737140.6.6.911-
dc.identifier.urihttp://hdl.handle.net/2436/15805-
dc.descriptionMetadata onlyen
dc.description.abstractHodgkin's lymphoma is one of the most common lymphoid cancers, particularly among young adults. Although there have been dramatic improvements in the treatment of Hodgkin's lymphoma, leading to high cure rates in some groups, current combination chemotherapy regimes are associated with significant secondary complications in long-term survivors. Furthermore, although a proportion of patients with Hodgkin's lymphoma will be cured, there still remains a significant rate of relapse and also a smaller proportion of poor responders who will go on to die of their disease. Therefore, developments in the treatment of Hodgkin's lymphoma must be directed at improving cure rates and reducing the burden of secondary complications. In recent years, the underlying pathogenesis of Hodgkin's lymphoma has become better understood. In particular, it is emerging that a key pathogenic event in Hodgkin's lymphoma is protection from Fas-induced cell death. Recent studies by the authors' group, and others, have demonstrated that this is, in part, due to the expression by Hodgkin/Reed-Sternberg cells of the cellular Fas-associated death domain-like IL-1 converting enzyme (FLICE)-like inhibitory protein molecule, a potent inhibitor of Fas-induced death. In this review, the role of cellular FLICE-like inhibitory protein in the pathogenesis of Hodgkin's lymphoma will be explored and also the possibility of targeting this molecule in order to provide an alternative and potentially safe approach to the treatment of Hodgkin's lymphoma will be investigated.en
dc.language.isoenen
dc.publisherFuture Drugsen
dc.relation.urlhttp://www.expert-reviews.com/doi/abs/10.1586/14737140.6.6.911-
dc.subjectHodgkin’s lymphomaen
dc.subjectLymphoid cancersen
dc.subjectTreatmenten
dc.subjectCancer treatment-
dc.titleTargeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.en
dc.typeArticleen
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.